|Dr. Ascher Shmulewitz||Chairman & CEO||401k||N/A||1956|
|Mr. Oz Adler CPA||Chief Financial Officer||209k||N/A||1987|
|Dr. Adi Zuloff-Shani||Chief Technology Officer||258k||N/A||1968|
Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110 for the treatment of Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Givatayim, Israel.
Therapix Biosciences Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.